United Therapeutics Corporation Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
United Therapeutics Corporation (UTHR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $534.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-05
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $265.30M, a 12.79% decline year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $269.00M, a 56.02% decline year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $485.50M, a 1.57% increase year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $182.50M, a 52.87% decline year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $1.58B, a 3.05% increase from fiscal 2024.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $1.54B, a 28.09% decline from fiscal 2023.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $2.14B, a 109.23% increase from fiscal 2022.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $1.02B, a 25.44% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $265.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $534.30M 10-Q · filed 2026-08-05 | $1.02B derived: sum of 3 quarters · filed 2026-08-05 | $1.20B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $269.00M 10-Q · filed 2026-05-06 | $754.50M derived: sum of 2 quarters · filed 2026-05-06 | $937.00M derived: sum of 3 quarters · filed 2026-05-06 | $1.24B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $485.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $668.00M derived: sum of 2 quarters · filed 2026-02-25 | $972.20M derived: sum of 3 quarters · filed 2026-08-05 | $1.58B 10-K · filed 2026-02-25 |
| 2025-09-30 | $182.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $486.70M derived: sum of 2 quarters · filed 2026-08-05 | $1.10B 10-Q · filed 2025-10-29 | $1.58B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $304.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $915.90M 10-Q · filed 2026-08-05 | $1.39B derived: sum of 3 quarters · filed 2026-08-05 | $1.78B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $611.70M 10-Q · filed 2026-05-06 | $1.09B derived: sum of 2 quarters · filed 2026-05-06 | $1.48B derived: sum of 3 quarters · filed 2026-05-06 | $1.67B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $478.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $865.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.06B derived: sum of 3 quarters · filed 2026-02-25 | $1.54B 10-K · filed 2026-02-25 |
| 2024-09-30 | $387.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $583.70M derived: sum of 2 quarters · filed 2025-10-29 | $1.06B 10-Q · filed 2025-10-29 | $1.59B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $196.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $671.80M 10-Q · filed 2025-07-30 | $1.20B derived: sum of 3 quarters · filed 2026-02-25 | $1.61B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $475.30M 10-Q · filed 2025-04-30 | $1.00B derived: sum of 2 quarters · filed 2026-02-25 | $1.41B derived: sum of 3 quarters · filed 2026-02-25 | $1.90B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $526.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $934.40M derived: sum of 2 quarters · filed 2026-02-25 | $1.43B derived: sum of 3 quarters · filed 2026-02-25 | $2.14B 10-K · filed 2026-02-25 |
| 2023-09-30 | $407.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $900.90M derived: sum of 2 quarters · filed 2024-10-30 | $1.61B 10-Q · filed 2024-10-30 | $1.88B derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $493.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $1.20B 10-Q · filed 2024-07-31 | $1.47B derived: sum of 3 quarters · filed 2025-02-26 | $1.71B derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $709.70M 10-Q · filed 2024-05-01 | $978.30M derived: sum of 2 quarters · filed 2025-02-26 | $1.22B derived: sum of 3 quarters · filed 2025-02-26 | $1.60B derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $268.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $511.10M derived: sum of 2 quarters · filed 2025-02-26 | $889.60M derived: sum of 3 quarters · filed 2025-02-26 | $1.02B 10-K · filed 2025-02-26 |
| 2022-09-30 | $242.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $621.00M derived: sum of 2 quarters · filed 2023-11-01 | $752.90M 10-Q · filed 2023-11-01 | $1.12B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $378.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $510.40M 10-Q · filed 2023-08-02 | $877.00M derived: sum of 3 quarters · filed 2024-02-21 | $1.19B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $131.90M 10-Q · filed 2023-05-03 | $498.50M derived: sum of 2 quarters · filed 2024-02-21 | $807.10M derived: sum of 3 quarters · filed 2024-02-21 | $1.05B derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $366.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $675.20M derived: sum of 2 quarters · filed 2024-02-21 | $915.70M derived: sum of 3 quarters · filed 2024-02-21 | $1.37B 10-K · filed 2024-02-21 |
| 2021-09-30 | $308.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $549.10M derived: sum of 2 quarters · filed 2022-11-02 | $1.00B 10-Q · filed 2022-11-02 | $1.56B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $240.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $694.90M 10-Q · filed 2022-08-03 | $1.25B derived: sum of 3 quarters · filed 2023-02-22 | $1.57B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $454.40M 10-Q · filed 2022-05-04 | $1.01B derived: sum of 2 quarters · filed 2023-02-22 | $1.33B derived: sum of 3 quarters · filed 2023-02-22 | $1.54B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $558.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $874.00M derived: sum of 2 quarters · filed 2023-02-22 | $1.09B derived: sum of 3 quarters · filed 2023-02-22 | $1.52B 10-K · filed 2023-02-22 |
| 2020-09-30 | $315.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $529.50M derived: sum of 2 quarters · filed 2021-11-03 | $964.90M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $214.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $649.40M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $435.40M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $799.20M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $265.90M 10-K · filed 2021-02-24 | |||
| 2018-03-31 | $70.00M 10-Q · filed 2018-05-02 | |||
| 2017-12-31 | $20.00M 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |